Mereo BioPharma (MREO) Gains from Investment Securities (2023 - 2026)
Mereo BioPharma (MREO) posted quarterly Gains from Investment Securities of -$17000.0 for Q1 2026, up 95.91% year-on-year from -$8677.3 in Q1 2025, and up 94.22% on a QoQ basis from -$294000.0 in Q4 2025.
Mereo BioPharma (MREO) Gains from Investment Securities (2023 - 2026) Analysis & Trends
Mereo BioPharma (MREO) has reported Gains from Investment Securities for 4 consecutive years, with -$17000.0 the latest figure, recorded in Q1 2026.
- Quarterly Gains from Investment Securities rose 95.91% year-over-year to -$17000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$406000.0 (up 8.76% YoY) and the FY2025 annual result came in at -$805000.0, down 292.12% from the prior year.
- Gains from Investment Securities climbed to -$17000.0 in Q1 2026 per MREO's latest filing, from -$294000.0 in the prior quarter.
- Over the last five years, Gains from Investment Securities for MREO reached as high as $448000.0 in Q1 2024 and fell as low as -$542000.0 in Q1 2023.
- A 4-year average of -$54000.0 and a median of $21000.0 in 2024 frame the typical range for Gains from Investment Securities.
- Annual changes were most pronounced in 2024 — Gains from Investment Securities surged 182.66% — and 2025, when it tumbled 432.2%.
- Year by year, Gains from Investment Securities stood at $195000.0 in 2023, then plunged by 180.51% to -$157000.0 in 2024, then sank by 87.26% to -$294000.0 in 2025, then jumped by 94.22% to -$17000.0 in 2026.
- According to Business Quant data, Gains from Investment Securities over the past three periods registered -$17000.0, -$294000.0, and -$196000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Mereo BioPharma | 242.07 Mn | 242.07 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17,000.00 |
| Mar 31, 2026 | -17,000.00 |
| Dec 31, 2025 | -294,000.00 |
| Dec 31, 2025 | -294,000.00 |
| Sep 30, 2025 | -196,000.00 |
| Sep 30, 2025 | -196,000.00 |
| Jun 30, 2025 | 101,000.00 |
| Jun 30, 2025 | 101,000.00 |
| Mar 31, 2025 | -416,000.00 |
| Mar 31, 2025 | -416,000.00 |
| Dec 31, 2024 | -157,000.00 |
| Dec 31, 2024 | -157,000.00 |
| Sep 30, 2024 | 59,000.00 |
| Sep 30, 2024 | 59,000.00 |
| Jun 30, 2024 | 69,000.00 |
| Jun 30, 2024 | 69,000.00 |
| Mar 31, 2024 | 448,000.00 |
| Mar 31, 2024 | 448,000.00 |
| Dec 31, 2023 | 195,000.00 |
| Dec 31, 2023 | 195,000.00 |